Katherine McGlynn

Dr. Katherine McGlynn

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Hepatology
Verified
Journal Article
Closed access
PDF file
KMKatherine McGlynn
Katherine McGlynn
JPJessica L. Petrick
Jessica L. Petrick
HEHashem El-Serag
Hashem El-Serag

1 May 2015 in Clinics in Liver Disease
Verified
Journal Article
Closed access
KMKatherine McGlynn
Katherine McGlynn
JPJessica L. Petrick
Jessica L. Petrick
WLW. Thomas London
W. Thomas London

5 November 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
JPJessica L. Petrick
Jessica L. Petrick
AFAndrea A. Florio
Andrea A. Florio
AZAriana Znaor
Ariana Znaor
DRDavid Ruggieri
David Ruggieri
MLMathieu Laversanne
Mathieu Laversanne
KMKatherine McGlynn
Katherine McGlynn

1 May 2011 in Clinics in Liver Disease
Verified
Journal Article
Closed access
KMKatherine McGlynn
Katherine McGlynn
WLW. Thomas London
W. Thomas London

21 March 2016 in Cancer
Verified
Journal Article
Open access
PDF file
OMOxana V. Makarova‐Rusher
Oxana V. Makarova‐Rusher
SASean F. Altekruse
Sean F. Altekruse
TMTim S. McNeel
Tim S. McNeel
SUSusanna Ulahannan
Susanna Ulahannan
ADAustin G. Duffy
Austin G. Duffy
KMKatherine McGlynn
Katherine McGlynn
BACKGROUND: Hepatocellular carcinoma (HCC) incidence has been increasing in the United States for several decades; and, as the incidence of hepatitis C virus (HCV) infection declines and the prevalence of metabolic disorders rises, the proportion of HCC attributable to various risk factors may be changing.METHODS: Data from the Surveillance, Epidemiology, and End Results‐Medicare linkage were used to calculate population attributable fractions (PAFs) for each risk factor over time. Patients with HCC (n = 10,708) who were diagnosed during the years 2000 through 2011 were compared with a 5% random sample of cancer‐free controls (n = 332,107) residing in the Surveillance, Epidemiology, and End Results areas. Adjusted odds ratios (ORs) and PAFs were calculated for HCV, hepatitis B virus (HBV), metabolic disorders, alcohol‐related disorders, smoking, and genetic disorders.RESULTS: Overall, the PAF was greatest for metabolic disorders (32%), followed by HCV (20.5%), alcohol (13.4%), smoking (9%), HBV (4.3%), and genetic disorders (1.5%). The PAF for all factors combined was 59.5%. PAFs differed by race/ethnicity and sex. Metabolic disorders had the largest PAF among Hispanics (PAF, 39.3%; 95% confidence interval [CI], 31.9%‐46.7%) and whites (PAF, 34.8%; 95% CI, 33.1%‐36.5%), whereas HCV had the largest PAF among blacks (PAF, 36.1%; 95% CI, 31.8%‐40.4%) and Asians (PAF, 29.7%; 95% CI, 25.9%‐33.4%). Between 2000 and 2011, the PAF of metabolic disorders increased from 25.8% (95% CI, 22.8%‐28.9%) to 36% (95% CI, 33.6%‐38.5%). In contrast, the PAFs of alcohol‐related disorders and HCV remained stable.CONCLUSIONS: Among US Medicare recipients, metabolic disorders contribute more to the burden of HCC than any other risk factor, and the fraction of HCC caused by metabolic disorders has increased in the last decade. Cancer 2016;122:1757‐65. Published 2016. This article is a U.S. Government work and is in the public domain in the USA..

1 August 2013 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
TWTania M Welzel
Tania M Welzel
BGBarry I Graubard
Barry I Graubard
SQSabah Quraishi
Sabah Quraishi
SZStefan Zeuzem
Stefan Zeuzem
JDJessica A Davila
Jessica A Davila
KMKatherine McGlynn
Katherine McGlynn
Ased studies in the United States. METHODS: Persons ≥68 years diagnosed with HCC (n=6,991) between 1994 and 2007 were identified in the SEER-Medicare database. A 5% random sample (n=255,702) of persons residing in SEER locations were selected for comparison. For each risk factor, odds ratios (ORs), 95% confidence intervals (95% CI) and PAFs were calculated. RESULTS: As anticipated, the risk of HCC was increased in relationship to each factor: HCV (OR 39.89, 95% CI: 36.29–43.84), HBV (OR 11.17, 95% CI: 9.18–13.59), alcohol-related disorders (OR 4.06, 95% CI: 3.82–4.32), rare metabolic disorders (OR 3.45, 95% CI: 2.97–4.02), and diabetes and/or obesity (OR 2.47, 95% CI: 2.34–2.61). The PAF of all factors combined was 64.5% (males 65.6%; females 62.2%). The PAF was highest among Asians (70.1%) and lowest among black persons (52.4%). Among individual factors, diabetes/obesity had the greatest PAF (36.6%), followed by alcohol-related disorders (23.5%), HCV (22.4%), HBV (6.3%) and rare genetic disorders (3.2%). While diabetes/obesity had the greatest PAF among both males (36.4%) and females (36.7%), alcohol-related disorders had the second greatest PAF among males (27.8%) and HCV the second greatest among females (28.1%). Diabetes/obesity had the greatest PAF among whites (38.9%) and Hispanics (38.1%), while HCV had the greatest PAF among Asians (35.4%) and blacks (34.9%). The second greatest PAF was alcohol-related disorders in whites (25.6%), Hispanics (30.1%) and blacks (and 18.5%) and HBV in Asians (28.5%). CONCLUSIONS: The dominant risk factors for HCC in the United States among persons ≥68 years differ by sex and race/ethnicity. Overall, eliminating diabetes/obesity could reduce the incidence of HCC more than the elimination of any other factor....